The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the
likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of
which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin
on platelet function profiles have not yet been ascertained. It remains unclear if this
reduction in cardiovascular death is mediated by decreased platelet reactivity.